Comparison of distribution of clinical and treatment covariables with the presence or absence of CDKN2A/2B deletions
| Parameter . | CDKN2A/B deleted (n = 44) . | CDKN2A/B wild-type (n = 53) . | P . |
|---|---|---|---|
| Age | |||
| Median (range), y | 41 (19-64) | 41 (18-60) | .72 |
| Sex (female/male) (%) | 16 (39)/28 (64) | 23 (43)/36 (68) | .074 |
| WBC | .074 | ||
| Median (range), ×109/L | 41.0 (0.8-269) | 20.5 (1.1-250) | |
| n.a. (%) | 1 (2) | 1 (2) | |
| Breakpoint (%) | .539 | ||
| p190BCR-ABL1 | 21 (47) | 31 (59) | |
| p210BCR-ABL1 | 16 (36) | 17 (32) | |
| Other/n.a. | 3 (7)/2 (5) | 0/5 (9) | |
| Imatinib schedule (%) | .342 | ||
| Early | 30 (68) | 39 (74) | |
| Late | 14 (32) | 14 (26) | |
| Type of HSCT (%) | .598 | ||
| SIB | 12 (27) | 18 (34) | |
| MUD | 32 (73) | 34 (64) | |
| n.a. | 1 (2) | ||
| Conditioning regimen (%) | .134 | ||
| TBI-based | 36 (82) | 44 (83) | |
| No TBI | 8 (18) | 8 (15) | |
| n.a. | 1 (2) |
| Parameter . | CDKN2A/B deleted (n = 44) . | CDKN2A/B wild-type (n = 53) . | P . |
|---|---|---|---|
| Age | |||
| Median (range), y | 41 (19-64) | 41 (18-60) | .72 |
| Sex (female/male) (%) | 16 (39)/28 (64) | 23 (43)/36 (68) | .074 |
| WBC | .074 | ||
| Median (range), ×109/L | 41.0 (0.8-269) | 20.5 (1.1-250) | |
| n.a. (%) | 1 (2) | 1 (2) | |
| Breakpoint (%) | .539 | ||
| p190BCR-ABL1 | 21 (47) | 31 (59) | |
| p210BCR-ABL1 | 16 (36) | 17 (32) | |
| Other/n.a. | 3 (7)/2 (5) | 0/5 (9) | |
| Imatinib schedule (%) | .342 | ||
| Early | 30 (68) | 39 (74) | |
| Late | 14 (32) | 14 (26) | |
| Type of HSCT (%) | .598 | ||
| SIB | 12 (27) | 18 (34) | |
| MUD | 32 (73) | 34 (64) | |
| n.a. | 1 (2) | ||
| Conditioning regimen (%) | .134 | ||
| TBI-based | 36 (82) | 44 (83) | |
| No TBI | 8 (18) | 8 (15) | |
| n.a. | 1 (2) |
MUD, matched unrelated donor; SIB, HLA-matched sibling transplantation.